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ABSTRACT
Introduction: The therapeutic management of Parkinson’s disease (PD) is challenging and has not been
fully resolved. The main challenges include motor fluctuations and levodopa-induced dyskinesia.
Moreover, no disease-modifying or neuroprotective therapy is currently available.
Areas covered: This review focuses on α-synuclein aggregation inhibitors and their therapeutic role in
PD, with special attention to heat shock proteins, immunotherapy (active and passive), the potential of
targeting the Ser129 phosphorylation site, and the antibiotic possibilities.
Expert opinion: The induction of chaperones may provide beneficial strategy to target synucleinopa-
thies, but further investigations are needed to find the best options. The promising preclinical results
with immunotherapy suggest that it may be a valuable disease-modifying therapy in PD in the future.
Clinical trials are currently in the initial phases, and future studies need to confirm the beneficial
therapeutic effect in humans and clarify open questions as regards the exact mode of action and
potential safety concerns. In case of covalent modifications, phosphorylation of α-synuclein is of out-
standing importance; however, conflicting results and open questions exist which necessitate clarifica-
tion. In vitro results suggest that several antibiotics may also influence α-synuclein aggregation, but
these results are to be confirmed in the future.
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1. Introduction
The diseases that are characterized by an abnormal accumula-
tion of α-synuclein (α-Syn) aggregates within neurons, nerve
fibers, or glial cells are collectively referred to as α-synucleino-
pathies. The three main types of α-synucleinopathies are
Parkinson’s disease (PD), dementia with Lewy bodies (DLB),
and multiple system atrophy (MSA). These conditions affect
mainly the elderly population, thereby causing serious issues
in the aging societies. Among them the most common condi-
tion is PD, which has both familial and sporadic forms. The
prevalence of the disease is approximately 0.2% in the general
population, a number gradually increasing with age [1]. PD is
characterized by typical motor symptoms including tremor,
rigidity, and hypokinesia, and non-motor symptoms, such as
dementia, sleep disorders, emotional, cognitive, and beha-
vioral disorders, and depression. The pathological hallmarks
of PD are the degeneration of DA-ergic neurons in the sub-
stantia nigra pars compacta (SNpc, a brain region involved in
the control of routine movements) and the presence of Lewy
bodies (LBs).
In the pathogenesis of the sporadic form of the disease
(accounting for approximately 80% of all cases), mitochondrial
disturbances, oxidative stress, glutamate excitotoxicity, immu-
nological mechanisms, and protein aggregation have all been
heavily implicated; however, the exact etiology is still not fully
understood.
Genome-wide association studies (GWAS) and other
genetic studies have largely revealed the genetic background
of the familial forms of the disease. The main genetic muta-
tions, gene duplications, triplications, and susceptibility loci
that are directly linked to PD are well summarized in a recent
article [2]; in this review, we therefore focus only on the SNCA
mutations (i.e. the coding gene of the α-Syn protein), which
affect the protein aggregation potential.
The gold standard of PD therapy is based on long-term
dopamine (DA) replacement with 3,4-dihydroxy-L-phenylala-
nine (L-DOPA), the precursor of DA; however, this therapy
can unfortunately provoke side effects.
Because of these side effects and the lack of neuroprotec-
tive drugs available, the search for new therapeutic options
in PD is still intense, and the pharmacological manipulations
of α-Syn aggregation are in the limelight of these
investigations.
This review summarizes the preclinical and phase I and II
clinical studies in which α-Syn aggregation inhibitors are in the
spotlight.
2. α-Syn and its role in the pathomechanism of PD
After Alzheimer’s disease, PD and the DLB are the most com-
mon types of degenerative dementias in patients above
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65 years of age [3]. The common histological features in these
conditions include the presence of LBs and Lewy neurites in
the affected human brain tissues. Lewy neurites are abnormal
cells, which contain granular material and abnormal α-Syn
filaments.
Similarly, the main constituent protein of LBs is α-Syn;
however, more than 70 additional types of proteins have
been identified within LBs to date [4]. The most well-known
LB proteins are ubiquitin, neurofilament, microtubule-asso-
ciated protein (MAP) 1B, synphilin-1, tau, and parkin [4].
The assembly of LBs is summarized schematically in
Figure 1. When α-Syn loses its native conformation, it can be
aggregated to β-sheet-rich dimers/trimers and after that into
oligomers. These oligomers form protofibrils, which are the
basis of the fibrils. The increased number of these fibrils and
other above-mentioned proteins eventually form LBs.
Increasing evidence supports that the toxicity of α-Syn
originates from the oligomers and not from the fibrils of α-
Syn. For example Tanaka and his colleagues provided evi-
dence that the mature fibrils may not be the most pathogenic
α-Syn species and LBs may have a cytoprotective role by the
reduction of the toxic soluble α-Syn forms [5]. Other results
suggest that the accumulating α-Syn aggregates are located at
the presynaptic terminals, which may have a pathological
impact on synaptic function; moreover, this may result in the
loss of dendritic spines at the postsynaptic area in DLB [6]. An
important in vivo experiment proved the toxicity of the oligo-
mers by testing α-Syn mutants which promote oligomer or
fibril formations using a rat lentivirus system. In this way, it
was possible to investigate the loss of the DA-ergic neurons in
the substantia nigra. The most severe DA-ergic loss was
observed in those animals that carried α-Syn variants that
form oligomers (i.e. E57K and E35K), while those variants that
form fibrils very quickly were less toxic [7]. But what causes the
toxicity of these oligomers? There are several possible answers
and theories. The first theory postulates that they might create
pores in the cell membrane which finally cause cell death [8].
The other possibility is the accumulation of these oligomers
near the endoplasmatic reticulum (ER), resulting in ER stress,
contributing to neurodegeneration [9]. According to the third
theory, the aggregated extracellular α-Syn activates microglia,
which leads to inflammation and degeneration of the affected
neurons [10,11]. In addition to this, the accumulation of these
oligomers may also suppress long-term potentiation and over-
load the protein degradation systems (ubiquitin–proteasome
system and autophagy–lysosomal pathway), which mechan-
isms may also be responsible for the cell death [12,13]. The
above-mentioned evidence suggests that inhibition of α-Syn
fibrillation or dissolving fibrils may be a dangerous strategy
because toxic oligomers could be generated.
The six-exon-containing α-Syn gene (SNCA) is located on
chromosome 4q21. The encoded α-Syn is a 140-residue pro-
tein, which is phylogenetically conserved and abundantly
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Figure 1. Oligomerization and Lewy body formation. The SNCA gene encoding α-synuclein is located on chromosome 4q21. The 140-residue α-synuclein protein can
be present in two structural isoforms, including a native random coil monomer and a membrane-bound helical form. When the protein loses its native conformation,
it can be aggregated to β-sheet-rich dimers/trimers and subsequently into oligomers. These oligomers can form protofibrils that are elemental components of α-
synuclein fibrils. The accumulation of fibrils and other proteins (such as ubiquitin and Tau) eventually leads to the formation of Lewy bodies.
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expressed throughout the central nervous system (CNS)
[14]. Mutations in the SNCA gene are rare, but are usually
highly penetrant and generally cause early onset autosomal
dominant PD [15]. The most relevant mutations of this gene
are p.A53T, p.A30P, p.E46K, p.H50Q, and p.G51D [15–19].
These mutations have been shown to alter fibrillization
kinetics of the nascent protein. For example, A30P has a
reduced ability to form amyloid-like fibrils, but it has an
enhanced ability to form oligomers [20–22]. Moreover,
there are evidences indicating that the A53T, E46K, and
H50Q mutations accelerate fibril formation, whereas the
G51D mutation attenuates it in vitro [23–26]. There are
similar results with the recently identified A53E SNCA muta-
tion, which also attenuates fibril formation [27–29].
The nascent α-Syn protein is 14 kDa and is mainly localized
in the cell soma, nucleus, and the presynaptic terminal region
of the neurons. Generally, α-Syn is assumed to be unfolded,
forming a random coil, but some groups argue that α-Syn exists
as a native tetramer in cells [30–32]. Its primary structure is
divided into three domains: the N-terminal domain, a hydro-
phobic domain, and the C-terminal domain (Figures 2(a,b),
and 3).
The N-terminal domain (residues 1–60) is highly conserved
and normally unordered. However, this amphipathic domain
contains four 11-amino-acid-long imperfect repeats (KTKEGV
motif), which allow the domain to form a secondary structure
resembling two α-helices separated by a break. The amphipatic
nature of this domain and its ability to adopt an α-helical
secondary structure indicate that α-Syn is a membrane-bound
protein.
The other name of the hydrophobic domain (residues
61–95) is the non-Aβ component of plaque [non-amyloido-
genic component (NAC)]. This domain is located in the second
part of the second α-helix. It contains two imperfect repeats
and is responsible for oligomerization, with residues 71–82
being essential in the process [33,34]. In addition, NAC med-
iates the conformational switch from the random-coil struc-
ture to a β-sheet structure, which is important for aggregation.
This region has a phosphorylation site at Ser87.
The C-terminal domain (residues 96–140) has no character-
istic secondary structure, but it is negatively charged due to
the high number of acidic amino acids.
The amphipathic N-terminal and the hydrophobic NAC are
highly conserved among species, whereas the C-terminal
domain is variable in size and sequence [35].
The protein has a chaperone-like activity, with the proline-
rich residues 125–140 being critical for this feature [36].
Besides Ser129, other phosphorylation sites exist in the
C-terminal domain of the protein at Tyr125, Tyr133, and
Tyr136 [37].
As mentioned above, α-Syn exists primarily in a random coil
structure, covalent modifications (i.e. Ser129 phosphorylation)
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Figure 2. A schematic figure about the structure of α-synuclein. The protein can be divided into three distinct domains. The N-terminal amphipathic domain
contains the evolutionary conserved KTEGV motifs and the main mutations associated with familial PD are located in this region. This region is responsible for the
membrane binding as well. The hydrophobic NAC region is responsible for promoting aggregation. The C-terminal domain is negatively charged; it contains a Ca2
+-binding site and the main phosphorylation site at Ser129, which modulates α-synuclein aggregation.
Figure 3. The full sequence of the 140-residue α-synuclein protein. The protein has three domains: the N-terminal (1–60), the NAC (61–95), and the C-terminal domains (96–
140). The NAC region is underlined. The amphipathic and the NAC regions contain seven imperfect lysine-rich, highly conservedmotif repeats (KTKEGV), responsible for binding
lipids (bold). The main mutations are shown in light grey background (Ala53Thr, Ala30Pro, Glu46Lys, His50Gln, Gly51Asp, and Ala53Glu). Chaperone-mediated autophagy
recognition sites are marked with dark grey background. The main serine phosphorylation sites are shown in bigger font size (Ser87 and Ser129).
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and hydrophobic interactions [33] facilitate the polymerization
of various α-Syn proteins into an anti-parallel β-sheet confor-
mation [38], but other evidences suggest that it may have a
parallel, in-register arrangement of β-sheets too [39,40].
Moreover, lateral and linear hydrogen bonds further intensify
the aggregation potential, which results in fibril formation
(Figure 1). The aggregation of α-Syn is a critical step in the
pathogenesis of PD, and the association between α-Syn and
PD is supported by numerous facts.
The most compelling evidence is the observation that the
overexpression of α-Syn (either by the duplication or triplica-
tion of the SNCA gene) results in early onset familial PD,
similarly to point mutations which increase the aggregation
potential of α-Syn [16,41,42]. Another serious evidence is that
α-Syn is the primary constituent protein of LBs, which are
pathological hallmarks of PD. The findings of studies knocking
out the SNCA gene or taking advantage of the transgenic
overexpression of the wild-type or mutant protein in rodents
and flies have proved the in vivo relevance of α-Syn. Some of
these transgenic animal models have exhibited neuronal cell
death, dystrophic neurites, α-Syn aggregates, and alterations
in DA metabolism and release [43–45]. Transgenic mice
expressing A53T human α-Syn have been shown to develop
severe motor impairment accompanied by motor neuron axo-
nal degeneration and neuronal inclusions containing toxic α-
Syn fibrils [46,47]. Besides transgenic models, several other α-
Syn-based animal models have also been described. In lenti-
viral-based rat models of PD, a selective loss of nigral DA-ergic
neurons has been described together with the development
of α-Syn-containing inclusions [48,49]. In wild-type, non-trans-
genic mice, the intrastriatal injection of synthetic α-Syn fibrils
led to the cell-to-cell transmission and intraneuronal accumu-
lation of α-Syn, progressive loss of DA-ergic neurons in the
SNpc, DA depletion, and motor coordination impairment [50].
Another α-Syn-based animal model of PD utilized adeno-asso-
ciated viral vector to lead to overexpression of α-Syn in rodent
midbrain DA-ergic neurons. In this model, striatal axonal
degeneration, α-Syn-inclusions in dystrophic axons were fol-
lowed by a selective and progressive loss of nigral DA-ergic
neurons [51].
As a summary of the above, α-Syn has been implicated as a
primary contributor to PD development; therefore, inhibiting
its aggregation may serve as a therapeutic possibility.
3. Inhibitors of α-Syn aggregation
3.1. Heat shock proteins (Hsps)
The pathological hallmarks of PD include the progressive
accumulation of pathogenic protein formations and intracel-
lular inclusion bodies, resulting in the formation of LBs and
Lewy neurites. This indicates the relevance of an altered
protein metabolism in the pathogenesis of PD. The forma-
tion, quantity, folding, aggregation, and degradation of pro-
teins are key aspects in appropriate protein homeostasis.
The main roles of Hsps, molecular chaperones, and their
molecular assistants, the co-chaperones, include the stabili-
zation of the cytoskeleton, the maintenance of the cell cycle
and other basic cell functions, the exertion of anti-apoptotic
effects, the regulation of vesicle trafficking, and the main-
tenance of cellular homeostasis; however, focus is placed on
protein folding, re-folding and degenerative functions of
these molecules in this review. Hsps or molecular chaper-
ones are constitutively expressed and are highly conserved.
Their classification is based on their molecular weight.
Accordingly, we can distinguish between small Hsps,
Hsp40, Hsp60, Hsp70, Hsp90, and Hsp100 protein families.
The elimination of misfolded proteins is crucial to maintain
intracellular homeostasis, and the chaperones control the
turnover of these proteins. In vivo, the degradation of α-
Syn protein can take place in the ubiquitin–proteasome and
the autophagy–lysosomal pathways (macro-, micro- and cha-
perone-mediated autophagy) [52].
Following stress stimuli, the amount of unfolded proteins
increase, which evokes the expression of chaperones. This
mechanism is under the control of certain transcription factors
that include heat shock factor 1 (HSF-1), which plays a role in
the negative feed-back. In normal conditions, this factor exists
in form of an inactive monomer within the cytosol due to its
association with Hsp90 [53]. Stress stimuli can lead to the
dissociation of these two molecules and the translocation of
HSF-1 into the nucleus following phosphorylation and trimer-
ization, where it can induce the expression of Hsp70 and other
Hsps. After the accumulated chaperones reach a sufficient
level, Hsp90 inactivates HSF-1 again.
The first evidence for the role of Hsps in PD was provided
by pathological studies, in which Hsp90, 70, 60, 40, and 27
were identified within LBs [54–57]. After this observation,
experiments performed in in vitro cell lines, yeasts, fruitflies,
and mice provided further evidence indicating their role in PD.
In an early in vitro study, the PC12 cell line was used with 1-
methyl-4-phenylpyridinium (MPP+) as a model of PD. The
PC12 cells were heat shocked for 1 h at 41.5○C. When utilized
6 h before the addition of MPP+, this treatment significantly
inhibited the induction of cell death evoked by the toxin [58].
In another cell line, the administration of MPP+ increased the
expression of α-Syn mRNA, leading to protein accumulation
and aggregation. Both the application of heat shock and the
overexpression of HDJ-1 (a homolog of human Hsp40) inhib-
ited this enhancement in α-Syn mRNA expression, facilitated
the ubiquitination of α-Syn protein and increased the protea-
some activity [59]. Furthermore, there is evidence indicating
the protective role of Hsps in another in vitro toxin model of
PD, that is rotenone toxicity in rat brain slices [60].
When human wild-type α-Syn or the inherited mutants
(A53T or A30P) were expressed in Saccharomyces cerevisiae, a
brief heat shock provided striking protection by inhibiting α-
Syn-induced apoptosis [61].
In Drosophila melanogaster, directed expression of α-Syn
causes degeneration of DA-ergic neurons in the SNpc. This
DA-ergic neuronal loss can be ameliorated by directed expres-
sion of the molecular chaperone Hsp70 [55].
In mice, pretreatment with geldanamycin (a natural inhibi-
tor of Hsp90) mitigated the DA-ergic neurotoxicity induced by
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; a sys-
temically applicable prodrug of MPP+). The molecular
mechanisms underlying this neuroprotective effect are sug-
gested to include a reduction of cytosolic Hsp90 and an
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increase in Hsp70 levels, whereas the level of striatal nuclear
HSF-1 was found to be significantly enhanced upon geldana-
mycin pretreatment. On the basis of these, pharmacological
inhibition of Hsp90 may represent a potential therapeutic
strategy in PD [62].
Based on these experiments, these proteins may appear in
the future on the therapeutical palette of the neurodegenera-
tive diseases including PD [63,64].
From pharmacological point of view, potential chaperone-
mediated therapeutical strategies in PD can be divided into
four different approaches (Table 1).
The first strategy takes advantage of Hsp90 inhibitors
(Figure 4), an approach through which the level of HSF-1
increases, resulting in the expression of stress-induced pro-
teins, including Hsp70. The first molecule that entered the
clinical investigations was 17-AAG (tanespimycin) in 1999.
This is a geldanamycin analog, which was developed to over-
come the limitations of the original molecule: the poor blood–
brain barrier permeability and the liver toxicity [63]. Many
other inhibitors have subsequently been tested in cancer
trials; however, they may have beneficial effect in PD as well
[65]. Indeed, promising results have been published with gel-
danamycin (a natural Hsp90 inhibitor) in different in vitro and
in vivo models of PD [62,66,67]. Geldanamycin and its analogs
act by blocking the ATP-binding site on the N-terminal
domain of Hsp90. The molecule has been shown to be pro-
tective in murine and fruitfly models of PD [62,66]. Notably,
however, challenging results have also been published as
regards the relationship between Hsp90 and PD. Indeed, a
recent study revealed that Hsp90 prevented the aggregation
of α-Syn in an ATP-independent manner. The Hsp90 chaper-
one can form a strong complex with toxic α-Syn oligomers,
and these complexes are harmless and non-toxic to cells [114].
Along this line, the upregulation of chaperones by inhibiting
Hsp90 might as well decrease the anti-cytotoxic effect of
Hsp90, suggesting that it might be beneficial to target the
heat shock response without altering the Hsp90 activity [114].
The second therapeutical option can be the modulation of
HSF-1 transcription factor or other pathways activating Hsp70.
For example, celastrol treatment significantly reduced the
effect of MPTP in a murine model of PD. Celastrol is an
Hsp70 inducer, which evokes the hyperphosphorylation of
HSF-1 and thereby promotes its binding to the regulated
gene promoters. Furthermore, treatment with FLZ was protec-
tive against MPP+-induced neurotoxicity in several PD models
[68–70]. The FLZ compound (N-[2-(4-hydroxy-phenyl)-ethyl]-2-
(2,5-dimethoxy-phenyl)-3-(3-methoxy-4-hydroxy-phenyl)-acry-
lamide) is a novel squamosamide derivative, originating from
a Chinese herb. A recent study reported that FLZ treatment
could alleviate motor dysfunction and ameliorate DA-ergic
neuronal dysfunction in an α-Syn transgenic mouse model
by enhancing Hsp70 protein expression and downstream tran-
scriptional activity [68]. The study revealed that FLZ increased
the expression of Hip (a co-chaperone of Hsp70), augmenting
Table 1. Experimental and pharmacological manipulations with potential to target α-Syn aggregation.
Chaperone-related manipulations
[58,59,61] Heat shock
[62–67] Hsp90 inhibitors (e.g. geldanamycin, tanespimycin (17-AAG), alvespimycin (17-DMAG), SNX compounds (lead: SNX-0723)
[68–71] HSF-1 activators (e.g. arimoclomol, HSF-1A, celastrol, valproate, geranylgeranylacetone, squamosamide derivative FLZ)
[72,73] Virus-mediated overexpression of Hsps (i.e. Hsp70, Hsp40 (?), or HSF-1)
[74–77] CPP-mediated overexpression of Hsps (e.g. TAT-Hsp70, TAT-Hsp40, or TAT-HSF-1)
Immunotherapy
[78–84] Passive immunization (C-terminal-targeted As (e.g. 9E4, 1H7, 5C1, ab274, PRX002); N-terminal-targeted As (e.g. Syn303))
[85,86] Active immunization (e.g. PD01A, PD03A)
Modulating Ser129 phosphorylation state
[87–93] Targeted mutations (S129A) inhibiting phosphorylation (contradictory results)
[91–94] Targeted mutations (S129D or S129E) mimicking phosphorylation (contradictory results)
[95,96] Pharmacological modulation of involved kinases and phosphatases (contradictory results)
Small molecules interfering with α-Syn oligomerization and accumulation
[97–113] Inhibitors of α-Syn polymerization (e.g. rifampicin, ceftriaxone, various polyphenols, peptide inhibitors)
[104,110] α-Syn fibril destabilizers (e.g. various polyphenols)
[102] Activators of α-Syn clearance (e.g. rapamycin)
Abs: antibodies; α-Syn: alpha-synuclein; CPP: cell-penetrating peptide; HSF-1: heat shock factor 1; Hsp: heat shock protein; 17-AAG: 17-allylamino-17-demethox-
ygeldanamycin; 17-DMAG: 17-dimethylaminoethylamino-17-demethoxygeldanamycin; (?): questionable.
Figure 4. Schematic representation of the Hsp90 inhibitors galdenamycin and its derivative, tanespimycin.
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the activity of Hsp70, a phenomenon which may underlie the
observed beneficial effect. In conclusion, pharmacological
induction of Hsp70 chaperone may represent a potential ther-
apy for α-Syn-related diseases, including PD. The most rele-
vant molecules which influence the function of Hsp70 have
recently been comprehensively reviewed [71].
The third potential therapeutical strategy is the gene therapy,
in which both the DA-related strategies and the disease-modify-
ing possibilities deserve attention [115]. Among the latter, virus-
mediated upregulation of Hsp70 may represent a novel possibi-
lity for neuroprotection in PD. There are promising results with
Hsp70 gene transfer by a recombinant adeno-associated virus in
mice [72]. The virus-mediated Hsp70 upregulation significantly
reduced the MPTP-mediated apoptosis in the substantia nigra
and the associated decline in striatal DA levels and the number of
tyrosine hydroxylase-positive fibers. Another study investigating
the effect of adeno-associated virus vector-mediated overexpres-
sion of different Hsps in a CDCrel-1 (a toxic parkin substrate)-
overexpressing transgenic rat model of PD revealed the protec-
tive role of the overexpression of Hsp70 and H-BH, a constitu-
tively active form of HSF-1, but interestingly not of Hsp40 [73].
The fourth potential strategy is based on the cell-penetrating
peptide (CPP) technology, a method which has an important
advantage as compared with the virus-mediated approach: it
does not require stereotaxic surgery [71]. These small basic
protein domains are able to transport the Hsps or other com-
pounds through the cell membranes and across the blood–brain
barrier. Themost widely utilized basic domain is derived from the
trans-activator of transcription (TAT) peptide of the human
immunodeficiency virus [74]. After a fusion to TAT, Hsp70 (in
form of TAT-Hsp70) can penetrate into the cells, and the admin-
istration of this construct was able to protect DA-ergic neurons in
midbrain cultures and in the substantia nigra in models of PD
[75]. In addition to the CPP-mediated delivery of Hsp70 per se,
beneficial results have also been reportedwith that of Hsp40 and
HSF-1 [76,77]. The CPP technology may be of outstanding rele-
vance in future studies.
3.2. Immunotherapy
In recent years, immunotherapeutical approaches have been in
the spotlight of research aiming at the development of effective
disease-modifying therapies in PD. Immunotherapy may be used
to target different aspects of α-Syn-mediated toxicity, which
include the prevention of the propagation of α-Syn aggregation,
and the facilitation of the clearance of already existing toxic
aggregates by promoting autophagy or macrophage activation.
The two main forms of immunotherapy are active and passive
immunization, with both having advantages and disadvantages.
Active immunization, also known as vaccination, refers to the
administration of a special antigen which in turn evokes the
activation of the patient’s immune system. Vaccination requires
a well-functioning immune system capable of producing an effi-
cient amount of antibodies; active immunization is, therefore, not
suitable for immunodeficient patients. On the other hand, vacci-
nation is cheap and does not require frequent administration.
Passive immunization refers to the administration of the prepro-
duced antibodies. This method is more expensive and requires
regular administration; however, it is also more controlled [78,85].
The majority of in vivo passive immunization studies pub-
lished so far have been conducted in different transgenic
murine models. In some studies, acute models were used, in
which either preformed fibrils of α-Syn were injected in wild-
type mice or an adeno-associated virus-mediated α-Syn over-
expression was achieved [78]. The first efficient passive immu-
nization study was reported in 2011, in which PDGF-hu-wt-
aSyn mice (line D) were injected with anti-C-terminal mouse
monoclonal antibody, 9E4 (epitope aa 118–126, mIgG1). The
histological examination confirmed a significant reduction of
C-terminally truncated α-Syn aggregates in parallel with beha-
vioral and cognitive improvements [78,79]. In the following
years, several studies targeting the C-terminal part of α-Syn in
transgenic models reported similar motor and behavioral
improvements together with histologically confirmed reduc-
tion of α-Syn [78,80–82]. Furthermore, there are data already
available with passive immunization targeting the N-terminal
of α-Syn. Syn303, an antibody targeting the N-terminal of α-
Syn was investigated in an acute model, where preformed
fibrils of α-Syn were injected in wild-type mice. In this
model, Syn303 not only reduced motor deficits, but also ame-
liorated DA-ergic neuronal degeneration [78,83]. In another
study, a virus-mediated α-Syn overexpression was used in
rats. In this case, two different pools of goat polyclonal anti-
bodies were applied, raised either against the N-terminal or
the midpart of α-Syn. The first pool directed against the
N-terminal was more effective and led to a decrease of α-Syn
accumulation as well as reduced neuroinflammation [78,84].
Based on the promising preclinical studies, passive immuniza-
tion therapies entered the clinical phases of investigation. To
date, only one phase I trial has been completed, which
involved 41 healthy volunteers and tested PRX002 (hIgG1), a
humanized form of an antibody previously tested in animal
models (NCT02095171). PRX002 was administered intrave-
nously in ascending doses, and the results confirmed the
ability of the candidate to significantly lower the free α-Syn
level in the plasma [78]. No serious treatment-related adverse
events were reported [78].
Among the active immunization approaches, short pep-
tides called AFFITOPEs by Affiris AG reached the clinical
phase of investigation. These peptides mimic the C-terminal
region of α-Syn, but their sequence is not completely identical
to the original peptide [85]. AFFITOPE vaccines, PD01A and
PD03A, were previously tested in transgenic murine models,
where both vaccines provided remarkable improvements. In
these animal models, vaccines resulted in a reduction of
aggregated α-Syn level in the neurons, ameliorated the neu-
rodegenerative processes, and improved motor and cognitive
functions as well [85,86]. The first clinical trial with one of the
AFFITOPE vaccines, PD01A was completed and demonstrated
a favorable safety profile (NCT01568099) [85]. Long-term fol-
low-up and application of a booster vaccine were included in
two recently completed clinical trials, but the results are not
yet available (NCT01885494 and NCT02216188).
3.3. Targeting Ser129 phosphorylation
Investigations on the possible post-translational modifications
of α-Syn revealed the presence of ubiquitination, sumoylation,
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oxidation, nitration, C-terminal truncation, and phosphoryla-
tion sites in this protein [116–120]. There is increasing evi-
dence indicating the relevance of phosphorylation of α-Syn in
oligomerization, fibrillogenesis, LB formation, and eventually
neurotoxicity. The majority of α-Syn is phosphorylated at
Ser129 in the LBs in PD and other synucleinopathies [120–
123]. To date the most relevant identified kinases, which
phosphorylate α-Syn at Ser129 are: casein kinases (CK1 and
CK2), the G protein-coupled receptor kinases (GRKs 1, 2, 5, and
6), human rhodopsin kinase-5, dual-specificity-Yak1-related
kinase-1 (DYRK1), leucine rich-repeat kinase 2 (LRRK2), and
polo-like kinases (PLKs 1, 2, and 3) [87,122,124–129]. The
most important kinase in case of tyrosine phosphorylation is
Abl kinase [130]. Protein phosphatase 2A has been shown to
play important role in dephosphorylation of α-Syn [131].
The importance of phosphorylation was strengthened by in
vitro, fruitfly, and murine models of PD (with human wild-type
or mutant protein expressed) [87–90,95]. In these models,
Ser129 phosphorylation was a key event in α-Syn-mediated
neurotoxicity [87].
In the first in vitro study, site-directed mutagenesis was
used to change Ser129 of α-Syn to alanine (S129A), which
abolished phosphorylation at this site in a human neuroblas-
toma cell line (H-SY5Ycells). The co-expression of wild-type α-
Syn and another LB component, synphilin-1, in this cell line
resulted in the formation of cytoplasmic eosinophilic inclu-
sions with features reminiscent of LBs, whereas that of
S129A α-Syn and synphilin-1 resulted in the development of
only few or no inclusions. Moreover, administration of 5,6-
dichloro-1-beta-D-ribofuranosylbenzimidazole, a casein kinase
2 inhibitor, diminished the number of the inclusions, whereas
H2O2, a molecule which increases α-Syn phosphorylation, aug-
mented the number of inclusions formed as results of the co-
expression of α-Syn, synphilin-1, and parkin [88].
In a subsequent in vitro experiment, rat oligodendroglial
cell line was utilized (OLN-93) to model MSA disease with the
co-expression of α-Syn and p25α, an oligodendroglial protein
which can stimulate α-Syn aggregation. The treatment of
these cells with the kinase inhibitor, 2-dimethylamino-4,5,6,7-
tetrabromo-1H benzimidazole, a molecule which targets
kinases such as casein kinase 2 and polo-like kinases, abro-
gated the toxicity. Ser129 phosphorylation was associated
with the formation of phosphorylated oligomers detectable
by immunoblotting, a process blocked by this inhibitor [89].
In a Drosophila PD model, S129A mutation interfered with
phosphorylation and suppressed the DA-ergic neuronal cell
death evoked by the expression of human α-Syn [87].
However, when Ser129 was replaced with the negatively
charged residue, aspartate (S129D, a phosphorylation mimic),
an enhanced α-Syn toxicity was detected.
Studies in mice using phosphoprotein phosphatase 2A
(PP2A), an enzyme which dephosphorylates α-Syn at Ser129,
revealed multiple alterations in the animals, including
enhanced neuronal activity, increased dendritic arborizations,
reduced astroglial, microglial activation, improved motor per-
formance, and reduced α-Syn aggregation [95].
However, there are conflicting results regarding this issue
[132]. Indeed, in a rat genetic PD model overexpressing
human α-Syn, PLK2 overexpression could reduce the accumu-
lation of the protein, suppress the dopaminergic neurodegen-
eration, and moderate hemiparkinsonian motor impairments
too [96]. This beneficial effect was dependent on the activity
of PLK2 and α-Syn phosphorylation; therefore, modulation of
its kinase activity may be a viable target for the treatment of
PD and other synucleinopathies [96]. In another rat model of
PD, recombinant adeno-associated virus was unilaterally
injected into the SNpc to overexpress human wild-type α-
Syn or one of the two human α-Syn mutants (S129A or
S129D). With this technique, the levels of human wild-type
or mutant α-Syn was about four times higher as compared
with the endogenous rat α-Syn. An increased rate of DA-ergic
neuronal cell death and a reduction of DA and tyrosine hydro-
xylase levels were measured in the S129A-transfected group
compared to that transfected by wild-type α-Syn.
Furthermore, no pathological changes were apparent in
S129D-treated rats. These results, therefore, suggest that the
non-phosphorylated form (S129A) could enhance the α-Syn-
induced nigral pathology, whereas Ser129 phosphorylation
(S129D) could abolish the α-Syn-induced nigrostriatal degen-
eration [91]. The investigation of biochemical, structural, and
membrane binding properties of wild-type α-Syn and its phos-
phorylation mimic forms (i.e. S129E, S129D) revealed that
phosphorylation of the wild-type protein at S129 augments
its conformational flexibility and inhibits fibrillogenesis in vitro,
whereas it does not perturb its membrane-bound conforma-
tion [92]. Moreover, Paleologou and her colleagues showed
that these phosphorylation mimics using acidic amino acid
residues are insufficient to reproduce the effect of phosphor-
ylation on the structural and aggregation properties of the
protein in vitro [92]. These results were supported by findings
of a study in a rat model of PD, investigating the effects of
S129A and S129D. In this study, S129A significantly increased
α-Syn toxicity, induced the formation of β-sheet-rich aggre-
gates, and increased its affinity for intracellular membranes.
On the other hand, S129D did not provoke DA-ergic cell
death, but intriguingly, larger aggregates were formed, and
apoptotic signals were also found to be activated. Accordingly,
this study concluded that phosphorylation is not important in
the accumulation of cytotoxic pre-inclusion aggregates [93].
Eventually, there are results indicating that the phosphor-
ylation status of α-Syn at Ser129 does not influence DA-ergic
neuronal cell death [93,94].
The phosphorylation sites are highly conserved among
species in case of α-Syn, and interestingly, only the Ser87
site is located within the NAC domain of the protein, a region
essential for aggregation and fibrillogenesis. Similarly to
Ser129 phosphorylation, these sites show enhanced phos-
phorylation in synucleinopathies as well as their transgenic
models [133]. In this study, Ser87 phosphorylation inhibited
the oligomerization and reduced the synuclein-membrane
interactions [133]. In the work of Oueslati et al., mimicking
phosphorylation at Ser87 inhibited α-Syn aggregation, result-
ing in a reduced toxicity and alleviated motor impairment in
rats. These results suggest that Ser87 phosphorylation plays a
regulatory role in α-Syn induced neuropathology and may
represent a valuable therapeutic strategy for the treatment
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of PD [134]. However, contradictory results also exist in this
field, as Ser87-phosphorylated α-Syn has a distinct morphol-
ogy and was found to be more neurotoxic as compared with
the wild-type protein [126].
Phosphorylation sites can be found in the C-terminal region
as well (i.e. Tyr125, Tyr133, and Tyr136), their role, however,
has not yet been clarified. It may be of importance, however,
that the degree of tyrosine phosphorylation of α-Syn was
shown to gradually decrease with age in both flies and
humans, with simultaneous development of DA-ergic neuro-
degeneration and inclusion body formation [37,90,92,135].
These results indicated that aging-related alterations in post-
translational modifications that influence protein aggregation
may be important in the development of PD and other neu-
rodegenerative disorders [37].
Summarizing these results, it is questionable that the
Ser129 phosphorylation promotes or inhibits α-Syn aggrega-
tion and neurotoxicity. However, this knowledge would be
essential to define the role of α-Syn in the pathogenesis of
PD and for the development of therapeutic strategies in this
degenerative disease.
3.4. The role of small organic molecules in α-Syn
aggregation
Antibiotics are widely used as antimicrobial agents to fight
infectious diseases. Since their appearance, an enhanced con-
trol of infectious diseases led to a significantly better outcome
and decreased mortality. In recent years, several antibiotics
again have become the focus of interest due to their newly
explored properties besides antimicrobial activity, such as anti-
inflammatory, antitumor, and possibly neuroprotective activity
(Figure 5) [97]. In this respect, rifampicin was first suggested to
have neuroprotective properties after the observation that its
use is associated with a decreased amyloid-β deposition and a
reduced incidence of dementia in leprosy patients [97,136].
Rifampicin was able to inhibit amyloid-β 1–4 peptide aggrega-
tion and fibril formation, and prevented amyloid-β induced
neurotoxicity [137]. A clinical study involving patients with
mild-to-moderate Alzheimer’s disease showed that rifampicin
was able to slow cognitive impairment measured by the
Standardized Alzheimer’s Disease Assessment Scale cognitive
subscale (SADAScog) [138]. However, a more recent multicen-
ter trial did not confirm these promising results [139].
Nevertheless, the inhibitory effect of rifampicin on amyloid-β
aggregation suggested that it may have a similar effect on α-
Syn as well. Accordingly, an in vitro study demonstrated that
rifampicin is able to stabilize α-Syn as a monomer and block
the fibrillation process; moreover, it was also able to disaggre-
gate existing fibrils [98]. Another in vitro study confirmed the
ability of rifampicin to prevent MPP+-induced toxicity in PC12
cells, increase their survival and reduce α-Syn oligomer forma-
tion [99]. Rifampicin has not yet been investigated in clinical
trials of PD, only in MSA, where a clinical trial of rifampicin
failed to demonstrate efficacy for slowing progression [100].
Ceftriaxone, a β-lactam antibiotic has also been suggested to
have neuroprotective capabilities. Ceftriaxone is well-tolerated
and is able to cross the blood–brain barrier. A recent study by
Ruzza et al. revealed that ceftriaxone is capable of specifically
binding to α-Syn and diminishing its polymerization in vitro [101].
In a murine model of PD, rapamycin was described to improve α-
Syn oligomer clearance by increasing autophagy, as measured
by an elevated immunoreactivity ofMAP light chain 3 (LC3) [102].
The promising results of in vitro and in vivo models suggest
that several antibiotics may be of therapeutic value in PD via
counteracting α-Syn aggregation. Importantly, rapamycin and
Figure 5. Schematic representation of three antibiotics with the potential to interfere with α-synuclein oligomerization and accumulation.
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ceftriaxone are both blood–brain barrier permeable; therefore,
they may reach the target areas and act directly in the affected
brain regions.
Polyphenols are natural compounds widely present in sev-
eral medicinal plants, vegetables and fruits, for example green
tea, grapes, red wine, apples, or strawberries. Several polyphe-
nols have been described to have antioxidant and anti-inflam-
matory properties, and have been suggested to have
neuroprotective capacities as well [97]. Several different poly-
phenolic compounds have been identified to have anti-fibril-
logenic or fibril-destabilizing effects and are therefore widely
studied in models of PD and Alzheimer’s disease as well. The
most well-known among these molecules is epigallocatechin
gallate (EGCG), which has been described to be able to pre-
vent fibrillogenesis of both α-Syn and amyloid-beta [103].
EGCG was also able to convert already existing α-Syn fibrils
into smaller, non-toxic aggregates [104]. In an MPTP-induced
model of PD, EGCG prevented α-Syn accumulation in the SNpc
[105]. In another study, a mixture of tea polyphenols inhibited
α-Syn oligomer accumulation in the striatum of MPTP-treated
monkeys and also reduced DA-ergic neuronal injury and
motor impairment. The main compound of this mixture was
also EGCG [106]. Besides EGCG, several other polyphenolic
compounds have been demonstrated to counteract α-Syn
fibrillation, such as quercetin, baicalein, or curcumin [97,107–
109]. Polyphenols have been confirmed to not only prevent α-
Syn aggregation but also to disaggregate existing α-Syn oli-
gomers [110]. The promising results with polyphenolic com-
pounds suggest that they warrant further investigations to
confirm their potential therapeutic value in in vivo models to
identify the possibility of future drug development.
Another interesting approach to counteract α-Syn aggre-
gation is the designing of peptide inhibitors. Identifying
residues 64–100 as a binding region of α-Syn led to the
development of short peptides containing this region,
which were able to inhibit α-Syn aggregation [111].
Another group identified residues 77–82 as a key region
for protein aggregation and designed an N-methylated
peptide containing this region, which was able to inhibit
α-Syn aggregation [112]. Based on these results, several
small peptide inhibitors have been synthesized using a
multiplexed intracellular protein-fragment complementa-
tion assay library screening system. Among these, a peptide
inhibitor was created which successfully abolished α-Syn
aggregation and prevented its toxicity [113]. The results of
these investigations point to the possibility of using pep-
tide inhibitors as novel drug candidates to develop disease-
modifying therapies for PD.
4. Conclusions
Results from genetic, neuropathological, and biochemical stu-
dies indicate that α-Syn represents an important therapeutic
target for synucleinopathies, including PD. Moreover genetic
studies with duplication or triplication drew the attention on
the importance of the quantity of α-Syn. According to this
hypothesis, the reduction of the total α-Syn level may be of
therapeutic benefit. This reduction can be achieved either by
downregulating the expression or enhancing the degradation
of the protein. Chaperones play essential roles in protein
folding and degradation, and their pharmacological manipula-
tion could provide therapeutic possibilities for synucleinopa-
thies. Altering post-translational modifications that influence
aggregation (e.g. phosphorylation) may represent a beneficial
target as well; however, the results are at present too contra-
dictory to permit final conclusion. Decreasing the toxic soluble
oligomeric species is of high importance.
Passive and active immunization targeting α-Syn have both
been tested in preclinical studies with promising results, and
initial-phase clinical trials are already underway.
Immunotherapeutical approaches may offer valuable future can-
didates for drug development.
Several antibiotics have been suggested to be able to
prevent α-Syn aggregation in vitro; however, these results
are only initial and need to be confirmed by both in vitro
and in vivo investigations. Polyphenolic compounds exhibited
promising anti-aggregation properties in in vitro and preclini-
cal studies, but further investigations are needed to confirm
their beneficial effects. In recent years, several peptide inhibi-
tors have been designed to counteract α-Syn aggregation, but
these investigations are only in very preliminary phase.
5. Expert opinion
After the promising results obtained from in vitro, yeast, and
Drosophila studies, intensive research has begun with chaper-
ones in synucleinopathies. The first of the four discussed
therapeutical possibilities takes advantage of Hsp90 inhibition,
which leads to enhanced Hsp70 formation. At the same time,
however, Hsp90 was also found to prevent α-Syn from aggre-
gating in an ATP-independent manner, resulting in the devel-
opment of harmless and non-toxic complexes [114].
Accordingly, Hsp90 inhibition may not be the most suitable
approach to enhance the expression of chaperones due to its
potential protective role. The second therapeutic option is the
modulation of HSF-1 or other mechanisms that elevate the
expression of Hsp70. This strategy is promising and can be
linked to the third option, gene therapy, an approach that can
be used to increase the expression of chaperones. Gene ther-
apy has both advantages and disadvantages. The most bene-
ficial advantage is its potential disease-modifying effect, and
the potential long-term alteration of gene expression by the
use of genome-integrated lentiviral vectors. The two main
disadvantages are craniotomy, an unavoidable potential
source of adverse events, and insertion mutagenesis, a phe-
nomenon which may appear when the viral vector integrates
into the host genome. In this respect, potential disease-mod-
ifying and neuroprotective approaches have come into the
spotlight, including the virus-mediated upregulation of cha-
perones. The main disadvantages of the recently applied viral
vectors include the low penetration through the blood–brain
barrier, the poor specificity to the target cells, the limitation of
the size of the transferred gene, the potential risks of immu-
nogenicity and carcinogenicity, and because of their low
penetration through the blood–brain barrier reaching their
target requires stereotaxic surgery [115]. Therefore, non-viral
vector-mediated alternative strategies are in the limelight of
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research. One of them is the CPP technology, which has an
important benefit as compared with the virus-mediated
approaches, as CPPs are able to transport the Hsps through
the blood–brain barrier and, therefore, craniotomy is not
necessary [71].
Although immunotherapy targeting α-Syn is in the early
phase of development, promising results have already been
published. However, there are a number of open questions
which still remain to be answered. Most data came from
animal models or in vitro studies. As regards animal experi-
ments, the use of different animal models in studies applying
passive immunotherapy and the fact that the different anti-
bodies were not compared in the same model represent an
important limitation [78]. These animal models differ in
respect of the presence of α-Syn, the extent of neurodegen-
eration, and the manifestation of behavioral and motor symp-
toms as well, which makes it difficult to draw general
conclusions. Furthermore, the applied antibodies were admi-
nistered in different dosing regimens. In the future investiga-
tions, it would be necessary to compare the different
antibodies targeting different regions of α-Syn in the same
animal model. It would also be interesting to compare the
antibodies in both the transgenic and acute animal models, as
it would promote the better understanding of the role of α-
Syn in the different stages of PD.
Active immunization has a number of advantages over
passive immunization techniques. It is cheaper and requires
less frequent administration. However, its therapeutic effect
strongly depends on the immune system of the patient, and it
is therefore less controlled. The delivery of antibodies into
brain is an important issue that can also be more efficiently
overcome by passive immunotherapy, as it is possible to
synthesize antibodies capable of penetrating the blood–brain
barrier [85].
Another important concern regarding immunotherapy is
the safety and the risk of potential vascular or autoimmune
adverse events. Animal studies are needed to investigate
these safety concerns, and the promising in vitro and in vivo
results need to be confirmed by clinical trials. To date, only the
first clinical trials have been initiated, and long-term follow up
studies need to clarify the long-term risks of immunothera-
peutical approaches [85]. Although a number of questions
need to be clarified, immunotherapy may be an effective
disease-modifying and neuroprotective therapy as it targets
underlying molecular mechanism and not only the symptoms.
Phosphorylation of proteins plays essential roles in their
biochemical and biological functions and may affect their
intracellular localization. Phosphorylation induces a conforma-
tional switch relevant in the regulation of protein–protein and
protein–ligand interactions. In this respect, the C-terminal
region deserves a special attention, as phosphorylation in
this region is likely to influence the affinity of α-Syn for other
proteins [37,140–143]. This protein is localized in different
parts of the cell, including the nucleus, mitochondria, and
lysosomal vesicles [14,37,144,145]; however, the physiological
role of α-Syn has not yet been clearly established. It is likely
that it has an important function in controlling synaptic neu-
rotransmission, possibly via the regulation of SNARE complex
integrity [37,146–149]. In this review, we summarized the
results of studies investigating the roles of the three main
phosphorylation sites of the protein, and concluded that the
main question, i.e. whether phosphorylation enhances or pro-
tects against α-Syn toxicity, still remains unresolved.
As regards Ser129 phosphorylation, the results are largely
based on gene overexpression studies using S129E/D and
S129A directed mutations. The most important criticism of
these works is that these substitutions do not reproduce all
aspects of phosphorylation, which may in part explain the
contradictory results. Besides the Ser129 phoshorylation site,
the Ser87 site has also been investigated in a few studies, and
the results are likewise contradictory. It would be necessary to
investigate the physiological role of Ser87 and its effect on the
protein function in wild-type and mutant α-Syn proteins both
in vitro and in vivo.
The main risk factor of neurodegenerative diseases such as
PD is aging, which gives a special importance to the observa-
tion indicating that tyrosine phosphorylation gradually
decreases with age and is further diminished in PD [90]. As
tyrosine phosphorylation of α-Syn may have neuroprotective
effects, its gradual decrease during aging may contribute to
the increased incidence of PD among the elderly; however,
this hypothesis needs confirmation.
In future studies, the further identification of kinases and phos-
phatases that are involved in regulating α-Syn phosphorylation
and dephosphorylation, respectively, should facilitate the under-
standing of the role of phosphorylation of α-Syn in PD
pathogenesis.
In recent years, several antibiotics have been proposed to
have neuroprotective properties besides their well-known
antimicrobial activity. To date, only limited data are available
from in vitro experiments and animal models [97]. The cur-
rently available data are promising, suggesting that rifampicin,
ceftriaxone, and rapamycin are able to diminish α-Syn aggre-
gation and may result in neuroprotection. However, these
data are at present insufficient to permit final conclusion,
and further confirmation is necessary by in vitro and in vivo
experiments, with the latter being essential to shed light on
crucial questions such as the optimal dose and duration of
therapy sufficient to achieve neuroprotection, as well as the
possible adverse effects.
Several polyphenolic compounds have been described to
prevent α-Syn aggregation in in vitro studies. EGCG has
already been tested in animal models as well, where it also
exerted beneficial effects not only by counteracting α-Syn
accumulation but also by preventing neuronal damage and
motor impairment. A growing number of evidence is available
suggesting the neuroprotective effects of polyphenols.
However, most data came from in vitro investigations or to a
lesser extent, from animal models. Human data are up to date
lacking, thereby future investigations are needed to assess
whether the preclinical results may be replicated in clinical
studies as well. In addition, further investigations are needed
to assess the safety, the necessary doses, and the duration of
the therapy to achieve neuroprotection.
Peptide inhibitors are a novel field in the development of
drugs which may prevent the toxic effects of α-Syn aggrega-
tion. So far only a limited number of peptide inhibitors have
been designed, which on the other hand, demonstrated
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promising effects against α-Syn aggregation and toxicity.
Further investigations are warranted to develop potent pep-
tide inhibitors, and to assess their possible adverse effects,
toxicity, degradation, and efficacy in animal models.
A growing number of investigations aim to target α-Syn aggre-
gation and thereby result in neuroprotection. However, most data
are currently only from in vitro studies or animal experiments, and
despite promising results there are also conflicting data available,
which raise more questions regarding the specificity of these
therapeutic attempts. Targeting α-Syn aggregation may be a
valuable future therapeutic option, but for most therapeutic
options, the exact mode of action, the therapy duration and
dosage and potential side effects need to be investigated.
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